Comparison of lotions, creams, gels and ointments for the treatment of childhood eczema: the BEE RCT
Health Technology Assessment · 2023
DOI: 10.3310/gzqw6681 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Health Technology Assessment, 2023. Verfasst von Matthew J Ridd und 21 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Academic Primary Care, Bristol Medical School, University of Bristol, Bristol, UK. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Eczema. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Technology Assessment programme.
Abstract (Originalsprache)
Background
Emollients are recommended for children with eczema (atopic eczema/dermatitis). A lack of head-to-head comparisons of the effectiveness and acceptability of the different types of emollients has resulted in a ‘trial and error’ approach to prescribing.
Objective
To compare the effectiveness and acceptability of four commonly used types of emollients for the treatment of childhood eczema.
Design
Four group, parallel, individually randomised, superiority randomised clinical trials with a nested qualitative study, completed in 2021. A purposeful sample of parents/children was interviewed at ≈ 4 and ≈ 16 weeks.
Setting
Primary care (78 general practitioner surgeries) in England.
Participants
Children aged between 6 months and 12 years with eczema, of at least mild severity, and with no known sensitivity to the study emollients or their constituents.
Interventions
Study emollients sharing the same characteristics in the four types of lotion, cream, gel or ointment, alongside usual care, and allocated using a web-based randomisation system. Participants were unmasked and the researcher assessing the Eczema Area Severity Index scores was masked. Main outcome measures The primary outcome was Patient-Oriented Eczema Measure scores over 16 weeks. The secondary outcomes were Patient-Oriented Eczema Measure scores over 52 weeks, Eczema Area Severity Index score at 16 weeks, quality of life (Atopic Dermatitis Quality of Life, Child Health Utility-9 Dimensions and EuroQol-5 Dimensions, five-level version, scores), Dermatitis Family Impact and satisfaction levels at 16 weeks.
Results
A total of 550 children were randomised to receive lotion (analysed for primary outcome 131/allocated 137), cream (137/140), gel (130/135) or ointment (126/138). At baseline, 86.0% of participants were white and 46.4% were female. The median (interquartile range) age was 4 (2–8) years and the median Patient-Oriented Eczema Measure score was 9.3 (SD 5.5). There was no evidence of a difference in mean Patient-Oriented Eczema Measure scores over the first 16 weeks between emollient types (global p = 0.765): adjusted Patient-Oriented Eczema Measure pairwise differences – cream–lotion 0.42 (95% confidence interval –0.48 to 1.32), gel–lotion 0.17 (95% confidence interval –0.75 to 1.09), ointment–lotion –0.01 (95% confidence interval –0.93 to 0.91), gel–cream –0.25 (95% confidence interval –1.15 to 0.65), ointment–cream –0.43 (95% confidence interval –1.34 to 0.48) and ointment–gel –0.18 (95% confidence interval –1.11 to 0.75). There was no effect modification by parent expectation, age, disease severity or the application of UK diagnostic criteria, and no differences between groups in any of the secondary outcomes. Median weekly use of allocated emollient, non-allocated emollient and topical corticosteroids was similar across groups. Overall satisfaction was highest for lotions and gels. There was no difference in the number of adverse reactions and there were no significant adverse events. In the nested qualitative study ( n = 44 parents, n = 25 children), opinions about the acceptability of creams and ointments varied most, yet problems with all types were reported. Effectiveness may be favoured over acceptability. Parents preferred pumps and bottles over tubs and reported improved knowledge about, and use of, emollients as a result of taking part in the trial.
Limitations
Parents and clinicians were unmasked to allocation. The findings may not apply to non-study emollients of the same type or to children from more ethnically diverse backgrounds.
Conclusions
The four emollient types were equally effective. Satisfaction with the same emollient types varies, with different parents/children favouring different ones. Users need to be able to choose from a range of emollient types to find one that suits them. Future work Future work could focus on how best to support shared decision-making of different emollient types and evaluations of other paraffin-based, non-paraffin and ‘novel’ emollients.
Trial registration
This trial is registered as ISRCTN84540529 and EudraCT 2017-000688-34. Funding This project was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (HTA 15/130/07) and will be published in full in Health Technology Assessment ; Vol. 27, No. 19. See the NIHR Journals Library website for further project information.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Centre for Academic Primary Care, Bristol Medical School, University of Bristol, Bristol, UK.
- Bristol Trials Centre, University of Bristol, Bristol, UK.
- National Institute for Health and Care Research Collaborations for Leadership in Applied Health Research and Care West, University Hospitals Bristol NHS Foundation Trust, Bristol, UK.
- Nottingham Support Group for Carers of Children with Eczema, Nottingham, UK.
- South West Medicines Information and Training, University Hospitals Bristol NHS Foundation Trust, Bristol, UK.
- Bristol Randomised Trials Collaboration, Bristol Trials Centre, University of Bristol, Bristol, UK.
ORCID-Profile: Matthew J Ridd, Sian Wells, Stephanie J MacNeill, Emily Sanderson, Douglas Webb, Jonathan Banks, Eileen Sutton, Alison Rg Shaw, Zoe Wilkins, Julie Clayton, Amanda Roberts, Kirsty Garfield, Lyn Liddiard, Tiffany J Barrett, J Athene Lane, Helen Baxter, Laura Howells, Jodi Taylor, Alastair D Hay, Hywel C Williams, Kim S Thomas, Miriam Santer
Förderung
- Health Technology Assessment programme
Zitieren
APA
Ridd, M. J., Wells, S., MacNeill, S. J., Sanderson, E., Webb, D., Banks, J., Sutton, E., Shaw, A. R., Wilkins, Z., Clayton, J., Roberts, A., Garfield, K., Liddiard, L., Barrett, T. J., Lane, J. A., Baxter, H., Howells, L., Taylor, J., Hay, A. D., …, & Santer, M. (2023). Comparison of lotions, creams, gels and ointments for the treatment of childhood eczema: the BEE RCT. Health Technology Assessment. https://doi.org/10.3310/gzqw6681
Vancouver
Ridd MJ, Wells S, MacNeill SJ, Sanderson E, Webb D, Banks J, et al. Comparison of lotions, creams, gels and ointments for the treatment of childhood eczema: the BEE RCT. Health Technology Assessment. 2023. doi:10.3310/gzqw6681
BibTeX
@article{Ridd2023,
author = {Ridd, Matthew J and Wells, Sian and MacNeill, Stephanie J and Sanderson, Emily and Webb, Douglas and Banks, Jonathan and Sutton, Eileen and Shaw, Alison Rg and Wilkins, Zoe and Clayton, Julie and Roberts, Amanda and Garfield, Kirsty and Liddiard, Lyn and Barrett, Tiffany J and Lane, J Athene and Baxter, Helen and Howells, Laura and Taylor, Jodi and Hay, Alastair D and Williams, Hywel C and Thomas, Kim S and Santer, Miriam},
title = {Comparison of lotions, creams, gels and ointments for the treatment of childhood eczema: the BEE RCT},
journal = {Health Technology Assessment},
year = {2023},
doi = {10.3310/gzqw6681}
}
EUVIMED